STOCKHOLM, Oct. 22, 2020 /PRNewswire/ -- Encouraging clinical safety data for ATOR-1017 The Phase I study with ATOR-1017 has progressed exceptionally well and in August we presented interim data that showed a good safety profile at clinically relevant dose levels. The dose evaluation will...
from PR Newswire: https://ift.tt/3dLBkXs
No comments:
Post a Comment